Bioavailability Study Of PF-00868554 Administered As 3x250mg Oral Tablets (Wet Granulate, 3x250mg Oral Tablets (Dry Granulate) And 750mg Solution Under Fed State

Overview

This study will test two different formulations. The results will be used to select formulation for phase 3.

Conditions

Interventions

Eligibility

Locations (1)

Outcomes